Description: MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the treatment of severe burns, chronic and other hard-to-heal wounds, and connective tissue disorders. Its lead product candidate is EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. The company is also developing NexoBrid for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Home Page: www.mediwound.com
MDWD Technical Analysis
42 Hayarkon Street
Yavne,
8122745
Israel
Phone:
972 7 797 14100
Officers
| Name | Title |
|---|---|
| Prof. Lior Rosenberg M.D. | Co-Founder & Medical Director |
| Mr. Boaz Gur-Lavie CPA, M.B.A. | Chief Financial Officer |
| Mr. Yaron Meyer Adv. | Exec. VP, Gen. Counsel & Corp. Sec. |
| Dr. Ety Klinger | Chief R&D Officer |
| Mr. Ofer Gonen B.Sc. | Chief Exec. Officer |
| Mr. Tzvi Palash B.Sc., M.Sc. | Chief Operating Officer |
| Mr. Stephen T. Wills CPA, CPA, MST | Exec. Director |
| Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Chief Medical Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 31.7321 |
| Price-to-Sales TTM: | 2.4803 |
| IPO Date: | 2014-03-20 |
| Fiscal Year End: | December |
| Full Time Employees: | 77 |